Former Stryker President to Chair Longeviti Neuro’s Board

Longeviti Neuro Solutions has chosen former Stryker Corp. president/chief operating officer (COO) Tim Scannell to chair its Board of Directors. The company also revealed a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad.

Scannell has a wealth of experience in the medical device market, having served in leadership positions with Stryker for more than 30 years. He advanced from sales and marketing to executive leadership roles highlighted by 10 years as group president of MedSurg & Neurotechnology and three years as president and COO of Stryker. He was responsible for helping select and develop the strategies and talent that delivers outstanding results today.

“Tim’s appointment as chair of the board brings leadership and unmatched insight from decades of success in building, and leading, high-performing medtech companies. His experience will be instrumental as we sharpen our strategy and deepen our impact in neurotechnology,” Longeviti Neuro Solutions Co-Founder/CEO Jesse Christopher said. “Coupled with the $10 million capital infusion from Soleus Capital, Longeviti now has the momentum to grow our team, advance critical research, and accelerate the development and delivery of life-changing solutions for patients with complex brain disorders.”

Scannell is currently scaling medtech businesses with his involvement as board representative and chair for multiple public and private companies, with the majority offering interaction with neurosciences and neurosurgeons. In his role as board chair, he will help formulate strategic plans and provide oversight while serving as a sounding board for management.

Longeviti established a strategic capital partnership with Soleus Capital, a healthcare investment firm based in Greenwich, Conn. The firm, which invests in the innovative areas of life sciences including medical technology, biotechnology, diagnostics, and life science tools, has committed $10 million in structured financing to fund key strategic priorities for Longeviti. With this capital, the company is poised to accelerate talent acquisition needs, continue development of its neurotechnology platforms, expand its market presence, and deliver life-changing innovations that enhance patient care.

“I easily said ‘yes’ to joining the Board of Directors for Longeviti, mainly because of the talent. I’ve known several of Longeviti’s leaders for years, and admire their tenacity, persistence, and goals to make an instrumental difference in the neuro industry,” Scannell stated. “Longeviti’s technology is revolutionary and will support the advancement of patient care in neurosciences, creating a value for the industry, our shareholders, and employees. I’m honored to share my experiences and opinions to support the success of Longeviti.”

“We were introduced to Longeviti by a respected key opinion leader who had firsthand experience using their innovative products in clinical practice. We were impressed by the company’s mission and strong operating results,” Soleus Capital Partner Ben Lund added. “It was clear to us that with the right capital support, Longeviti could scale its team, reach more clinicians and patients, and amplify its impact on those living with complex brain disorders. We are proud to be part of that growth.” 

Longeviti Neuro Solutions develops functional neurotechnology solutions that improve the lives of patients with neurological conditions during and after surgery, while also returning them to anatomical normalcy. The Baltimore-based company has full manufacturing, packaging, designing, and sterilizing capabilities in-house with multiple U.S. Food and Drug Administration (FDA) clearances, successful FDA audits, and ISO 13485 certifications. Longeviti has 50 worldwide patents to date.

Longeviti aims to develop platform solutions for complex brain surgery. Its products are currently approved for use in more than 120 hospitals globally. To date, Longeviti neurosurgical implants have helped over 4,000 patients.

Founded in 2018, Soleus Capital currently has about $2 billion in assets under management. Soleus partners with public equity, private equity, and structured credit companies, and entities in each of the life sciences subsectors: biotechnology, medical technology, life sciences tools, and diagnostics.